{"id":80280,"date":"2025-07-15T11:31:24","date_gmt":"2025-07-15T11:31:24","guid":{"rendered":"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/?p=80280"},"modified":"2025-07-15T12:35:42","modified_gmt":"2025-07-15T12:35:42","slug":"ultracol-leads-a-clinical-study-published-in-seme-journal","status":"publish","type":"post","link":"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/?p=80280&lang=en","title":{"rendered":"Ultracol leads a clinical study published in SEME journal"},"content":{"rendered":"<p><strong>The prestigious <em>Revista de la Sociedad Espa\u00f1ola de Medicina Est\u00e9tica (SEME)<\/em> has published, in its issue no. 83 (2025), a multicentre clinical study that supports the efficacy and safety of injectable polydioxanone (PDO), specifically ULTRACOL 200, distributed by IT Pharma for aesthetic medical treatments.<\/strong><\/p>\n<h3>Practice-based clinical research<\/h3>\n<p>The article, titled <em>\u201cInjectable polydioxanone: efficacy and safety evaluation in aesthetic medicine\u201d<\/em>, was authored by <strong>Dr. Roberto Pedrero<\/strong>, <strong>Dr. Jes\u00fas Rom\u00e1n Mart\u00ednez<\/strong>, and <strong>Dr. Paloma Tejero<\/strong>. The study was based on a comprehensive survey conducted among <strong>84 Spanish-speaking aesthetic doctors<\/strong> from Spain, Mexico, Chile, and Ecuador, all of them with hands-on experience in the clinical use of Ultracol.<\/p>\n<p>The questionnaire was designed to collect data across three key areas: <strong>sociodemographic information and professional background<\/strong>; perception of the <strong>safety, efficacy, and satisfaction<\/strong> with injectable PDO; and the presence of <strong>adverse effects<\/strong>, whether immediate or delayed.<\/p>\n<p>One of the study\u2019s most relevant findings is that <strong>90% of the participating doctors rated Ultracol as safe, effective, and easy to apply<\/strong>, with cannula being the most commonly used application technique.<\/p>\n<h3>Key study results<\/h3>\n<p>Results were evaluated using a scoring scale from 1 to 5. The most significant ratings were:<\/p>\n<ul>\n<li><strong>Product safety:<\/strong> 4.7<\/li>\n<li><strong>Improvement in skin quality:<\/strong> 4.3<\/li>\n<li><strong>Professional satisfaction:<\/strong> 4.1<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>It is worth noting that doctors with more than 10 years of experience gave even higher ratings for treatment efficacy, reinforcing the value of Ultracol in expert hands.<\/p>\n<h3>High clinical safety<\/h3>\n<p>The study also highlights the excellent safety profile of the product. <strong>No serious adverse events<\/strong> were reported. Minor and temporary reactions such as erythema, bruising, or mild swelling were the only side effects observed. In fact, <strong>73% of physicians reported no adverse effects at all<\/strong>.<\/p>\n<p style=\"text-align: center;\"><strong><em>0% serious adverse reactions.<\/em><\/strong><\/p>\n<h3>Ultracol and innovation in biostimulation<\/h3>\n<p>Ultracol is the first and only <strong>collagen stimulator formulated with polydioxanone (PDO) in the form of microspheres<\/strong>, a biodegradable and biocompatible material. A single vial is equivalent to more than 1,000 monofilament threads (29G 38 50)<\/p>\n<p>Thanks to its ability to <strong>stimulate the synthesis of collagen types I and III<\/strong>, Ultracol improves the skin\u2019s firmness, elasticity, and texture. Its <strong>controlled biodegradation process, which completes in approximately six months,<\/strong> allows for long-lasting, visible results with no residue left in the tissue.<\/p>\n<p>Its presentation in <strong>lyophilised vials<\/strong> allows for flexible and personalised reconstitution according to treatment needs. It is indicated for use on the <strong>face, neck, neckline, and body areas,<\/strong> including mobile zones where progressive structural improvement is desired without excessive volume.<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-80270 size-full\" src=\"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/wp-content\/uploads\/2025\/07\/Imagen1.jpg\" alt=\"imagen1\" width=\"525\" height=\"331\" srcset=\"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/wp-content\/uploads\/2025\/07\/Imagen1.jpg 525w, https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/wp-content\/uploads\/2025\/07\/Imagen1-300x189.jpg 300w, https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/wp-content\/uploads\/2025\/07\/Imagen1-64x40.jpg 64w\" sizes=\"(max-width: 525px) 100vw, 525px\" \/><\/p>\n<h3>Study conclusion<\/h3>\n<p>The study published by SEME supports the use of <strong>Ultracol as a benchmark injectable PDO<\/strong> in aesthetic medicine, highlighting its clinical efficacy, safety in real-world practice, and high levels of satisfaction among both practitioners and patients.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Read the full article in SEME Journal No. 83: <a href=\"https:\/\/www.seme.org\/revista\/articulos\/polidioxanona-inyectable-estudio-de-valoracion-de-su-eficacia-y-seguridad-en-medicina-estetica\">www.seme.org\/revista<\/a><\/strong><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The prestigious Revista de la Sociedad Espa\u00f1ola de Medicina Est\u00e9tica (SEME) has published, in its issue no. 83 (2025), a multicentre clinical study that supports the efficacy and safety of injectable polydioxanone (PDO), specifically ULTRACOL 200, distributed by IT Pharma for aesthetic medical treatments. Practice-based clinical research The article, titled \u201cInjectable polydioxanone: efficacy and safety [&hellip;]<\/p>\n","protected":false},"author":94,"featured_media":80271,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","footnotes":""},"categories":[877],"tags":[],"class_list":{"0":"post-80280","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sin-categoria-en"},"_links":{"self":[{"href":"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/index.php?rest_route=\/wp\/v2\/posts\/80280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/index.php?rest_route=\/wp\/v2\/users\/94"}],"replies":[{"embeddable":true,"href":"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=80280"}],"version-history":[{"count":6,"href":"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/index.php?rest_route=\/wp\/v2\/posts\/80280\/revisions"}],"predecessor-version":[{"id":80291,"href":"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/index.php?rest_route=\/wp\/v2\/posts\/80280\/revisions\/80291"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/index.php?rest_route=\/wp\/v2\/media\/80271"}],"wp:attachment":[{"href":"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=80280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=80280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fervent-dubinsky.82-165-171-139.plesk.page\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=80280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}